drugset
drugset / Trial / NCT04485481

Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers

NCT04485481 ↗

Phase 1 Completed 42 enrolled Q32 Bio Inc.
RandomizedParallel-groupQuadruple-blindOther

Summary

A two (2) part study to evaluate the safety, tolerability and PK of ADX-914

Timeline

Start
2020-09-08
Primary completion
2022-01-12
Completion
2022-01-12

Drugs

EvaluationDrugModalityDoseRoute
Subject bempikibart Monoclonal antibody 0.1 mg/kg Subcutaneous

Indications

No indication recorded.